secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENZO BIOCHEM INC (—)
CIK:        0000316253
Form:       8-K
Filed at:   2024-02-01T23:59:59+00:00
Accession:  0001213900-24-008745
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enzo Biochem names permanent CEO and CFO; shareholders reject say-on-pay
------------------------------------------------------------------------

- Kara Cannon appointed permanent CEO (was interim since Sept 2023); Patricia Eckert appointed permanent CFO.
- Shareholders elected directors Pully, Radoff, Tagliaferri, Cannon; Radoff and Tagliaferri had narrow margins.
- Non-binding advisory vote on executive compensation rejected: 13.9M for vs 17.3M against.
- Shareholders ratified EisnerAmper as independent auditor for FY2024 ending July 31, 2024.
- 44.4M shares (87.94%) represented at meeting; quorum present.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/316253/000121390024008745/0001213900-24-008745-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/316253/000121390024008745/ea192624-8k_enzobiochem.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-008745

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer